Passage Bio, Inc. Common Stock (PASG)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Passage Bio, Inc. Common Stock (PASG) is listed on Nasdaq, where it has traded since February 28, 2020.
- Listed On
- Nasdaq
- Listed Since
- February 28, 2020
- Employees
- 24
- Market Cap
- $15M
About Passage Bio, Inc. Common Stock
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 28 institutions reported holding PASG, with 4.3 million shares worth $11.1 million in aggregate. The largest reported holder was Citadel Advisors, with 2.9 million shares worth $4.3 million. Of the 5 largest holders listed below, 2 opened new positions in PASG, 2 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Citadel Advisors | 2,886,125 | $4M | New position |
| Lynx1 Capital Management | 673,759 | $3M | Added 8.03% |
| Vanguard | 131,651 | $642K | Unchanged |
| Balyasny Asset Management | 107,025 | $522K | New position |
| Ikarian Capital | 99,517 | $486K | Added 46.08% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is PASG?
Passage Bio, Inc. Common Stock (PASG) is listed on Nasdaq, where it has traded since February 28, 2020.
Who are the largest institutional holders of PASG?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of PASG were Citadel Advisors, Lynx1 Capital Management and Vanguard.
How many institutions own PASG?
28 institutions reported a position in PASG for the quarter ended June 30, 2026, worth $11.1 million in total.
Did institutions buy or sell PASG last quarter?
Of the 5 largest reported holders, 2 opened new positions in PASG, 2 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for PASG.
Every reported institutional holder, plus insider and congressional trades in PASG, on SentiSense.